...
首页> 外文期刊>Applied Microbiology and Biotechnology >Enzymatic synthesis of avermectin B-1a glycosides for the effective prevention of the pine wood nematode Bursaphelenchus xylophilus
【24h】

Enzymatic synthesis of avermectin B-1a glycosides for the effective prevention of the pine wood nematode Bursaphelenchus xylophilus

机译:AvEcectin B-1A糖苷的酶促合成,用于防止松木线虫Bursaphelenchus Xylophilus的预防

获取原文
获取原文并翻译 | 示例

摘要

Avermectin produced by Streptomyces avermitilis is an anti-nematodal agent against the pine wood nematode Bursaphelenchus xylophilus. However, its potential usage is limited by its poor water solubility. For this reason, continuous efforts are underway to produce new derivatives that are more water soluble. Here, the enzymatic glycosylation of avermectin was catalyzed by uridine diphosphate (UDP)-glycosyltransferase from Bacillus licheniformis with various UDP sugars. As a result, the following four avermectin B-1a glycosides were produced: avermectin B-1a 4aEuro(3)-beta-d-glucoside, avermectin B-1a 4aEuro(3)-beta-d-galactoside, avermectin B-1a 4aEuro(3)-beta-l-fucoside, and avermectin B-1a 4aEuro(3)-beta-2-deoxy-d-glucoside. The avermectin B-1a glycosides were structurally analyzed based on HR-ESI MS and 1D and 2D nuclear magnetic resonance spectra, and the anti-nematodal effect of avermectin B-1a 4aEuro(3)-beta-d-glucoside was found to exhibit the highest activity (IC50 = 0.23 mu M), which was approximately 32 times greater than that of avermectin B-1a (IC50 = 7.30 mu M), followed by avermectin B-1a 4aEuro(3)-beta-2-deoxy-d-glucoside (IC50 = 0.69 mu M), avermectin B-1a 4aEuro(3)-beta-l-fucoside (IC50 = 0.89 mu M), and avermectin B-1a 4aEuro(3)-beta-d-galactoside (IC50 = 1.07 mu M). These results show that glycosylation of avermectin B-1a effectively enhances its in vitro anti-nematodal activity and that avermectin glycosides can be further applied for treating infestations of the pine wood nematode B. xylophilus.
机译:由Streptomyces Avermitilis生产的Avermectin是针对松木线虫Bursaphelenchus Xylophilus的抗鸣蛇膜。然而,其潜在的用途受其水溶解度差的限制。因此,正在进行不断的努力来产生更多水溶性的新衍生物。这里,Avermectin的酶促糖基化催化通过来自芽孢杆菌的甲硝酸甲酸酯(UDP) - 甲硝酸甘氨酸与各种UDP糖催化。结果,制备了以下四种Avermectin B-1A糖苷:Avermectin B-1A 4Aeuro(3)-Beta-D-葡萄糖苷,AvElmectin B-1a 4aeuro(3)-Beta-D-半乳糖糖苷,Avermectin B-1a 4aeuro (3)-beta-l-岩岩,和Avermectin b-1a 4aeuro(3)-beta-2-脱氧-d-葡糖苷。基于HR-ESI MS和1D和2D核磁共振谱进行结构分析AVERMECTIN B-1A糖苷,发现AVERMECTIN B-1A 4AEURO(3)-β-D-葡糖苷的抗鸣曲效应表现出来最高的活性(IC50 =0.23μm),比Avermectin B-1a(IC50 =7.30μm)大约32倍,然后是Avermectin b-1a 4aeuro(3)-beta-2-脱氧-d-葡萄糖苷(IC50 =0.69μm),Avermectin b-1a 4aeuro(3)-beta-l-岩藻糖苷(IC50 = 0.89 mu m),Avemectin b-1a 4aeuro(3)-beta-d-半乳糖糖苷(Ic50 = 1.07 mu m)。这些结果表明,Avermectin B-1a的糖基化有效增强了其体外抗那肿性活性,并且可以进一步施加Avermectin糖苷,用于治疗松木线虫B.木膜的侵袭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号